Formycon Faces Choppy Waters Amid US Biosimilar Pricing Storm

Ustekinumab Pricing Bites; Cimerli ‘Paused’; Pembrolizumab Phase III Terminated

Unleashing a trio of major announcements, Formycon has indicated a gloomy outlook for US Stelara biosimilar pricing; revealed plans to pause commercialization of its Sandoz-partnered US Cimerli rival to Lucentis amid discounting from rivals; and set out ambitious plans to win FDA approval for its proposed Keytruda biosimilar without any Phase III data.

Formycon is facing stormy market conditions in biosimilars (Shutterstock)

More from Biosimilars

More from Policy & Regulation